Clinical trial NCT00580931: Safety Study of Nicotinamide to Treat Alzheimer's Disease
Official title: Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Alzheimer's Disease
Keywords: nutraceutical, dementia, cognition, HDAC inhibitor
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
Collaborators: name: Alzheimer's Association
First posted: 2007-12-27
Enrollment: 50
Sex: ALL
Minimum age (years): 50
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

Detailed description: The goal of this proposal is to show that, nicotinamide (NA), a B3 vitamin, is safe and effective for the treatment of patients with mild to moderate Alzheimer's disease (AD). NA is known to block the ability of certain proteins to regulate other proteins by removing their acetyl groups. Recent evidence has demonstrated that inhibitors such as NA prevent nerve cell degeneration in models of Huntington's disease (HD), Parkinson's disease and Lou Gehrig's disease (or ALS). Despite these beneficial effects in many different animal models, there have been no studies to date using these inhibitors in AD. In some of our recent studies we found that the potent inhibitor, NA, significantly improves learning and memory in transgenic mice that develop AD. NA treatment also resulted in striking changes in tau, a protein that abnormally accumulates in AD. NA has been extensively used in clinical studies over the last 40 years and is generally safe and well-tolerated. As NA is a safe and readily available vitamin supplement, our recent results provide a strong argument for a study of NA in patients with AD. We therefore propose to treat 50 patients with mild to moderate AD with either NA (1500 milligrams twice a day) or an identical but inactive drug (placebo) for 24 weeks. At 6 week intervals we will assess functions such as learning and memory, and ability to carry out daily activities as well as caregiver reports using standardized tests. We will also perform spinal taps at the beginning and end of the study to measure the level of abnormal tau protein in the cerebrospinal fluid. Blood tests will periodically be done to assess liver function and complete blood counts. The results of this study may provide the basis for a more extensive study of NA for the treatment of mild to moderate AD.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of probable AD according to DSM-IV criteria
* Mild to moderate dementia based on Mini-Mental State Examination \[MMSE\] score between 13-25
* Minimum age 50 years
* Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD
* Hachinski Ischemic Score of \<4.
* Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine.

Exclusion Criteria:

* Dementia due to another cause
* Other neurological or psychiatric diseases
* Pseudodementia
* Unstable medical condition
* Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug
* History of alcoholism, drug abuse, liver disease, peptic ulcer disease
* Pregnancy, or the potential to become pregnant.

Primary outcomes:
measure: Alzheimer's Disease Assessment Scale-Cognitive Subscale
timeFrame: Baseline, 6 wk, 12 wk, 18 wk, 24 wk
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: UC Irvine School of Medicine
state: California
Study officials:
affiliation: Regents of the University of California
name: Steven S Schreiber, MD
role: PRINCIPAL_INVESTIGATOR
References: